

Peter Valent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/965483/publications.pdf>

Version: 2024-02-01

748
papers

44,207
citations

1994

101
h-index

4117

175
g-index

769
all docs

769
docs citations

769
times ranked

31064
citing authors

#	ARTICLE	IF	CITATIONS
1	Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues” Recommendations from the European <scp>LeukemiaNet</scp>. Cytometry Part B - Clinical Cytometry, 2023, 104, 15-26.	1.5	16
2	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDS&Flow</scp> Cytometry Working Group. Cytometry Part B - Clinical Cytometry, 2023, 104, 77-86.	1.5	18
3	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. Leukemia, 2022, 36, 516-524.	7.2	29
4	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 2022, 43, 280-299.	2.2	213
5	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer Discovery, 2022, 12, 372-387.	9.4	77
6	Structural and utational nalysis of ember-pecific STAT unctions. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130058.	2.4	3
7	<scp>PD&L1</scp> overexpression correlates with <scp><i>JAK2</i>&V617F</scp> mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. American Journal of Hematology, 2022, 97, 390-400.	4.1	8
8	The impact of <scp>COVID</scp>&19 on cancer care of outpatients with low socioeconomic status. International Journal of Cancer, 2022, 151, 77-82.	5.1	15
9	A series of case studies illustrating the role of flow cytometry in the diagnostic work&cup of myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2022, , .	1.5	5
10	Overexpression of Fc&uRI on Bone Marrow Mast Cells, but Not MRGPRX2, in Clonal Mast Cell Disorders With Wasp Venom Anaphylaxis. Frontiers in Immunology, 2022, 13, 835618.	4.8	5
11	The cancer survival index&”A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies. Cancer Medicine, 2022, 11, 3387-3396.	2.8	7
12	Multistep pathogenesis of chronic myelomonocytic leukemia in patients. European Journal of Haematology, 2022, , .	2.2	3
13	Impact of interest rates on forest management planning based on multi-criteria decision analysis. Central European Forestry Journal, 2022, 68, 23-35.	0.8	1
14	JAK&STAT core cancer pathway: An integrative cancer interactome analysis. Journal of Cellular and Molecular Medicine, 2022, 26, 2049-2062.	3.6	32
15	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1953-1963.	3.8	20
16	Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis. Journal of Clinical Oncology, 2022, 40, 1783-1794.	1.6	24
17	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User&”s Guide for Daily Clinical Practice. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1999-2012.e6.	3.8	35
18	Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematological Oncology, 2022, 40, 491-504.	1.7	0

#	ARTICLE	IF	CITATIONS
19	Reply to "Need to define a subgroup of patients with idiopathic mast cell activation syndrome". Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1128.	3.8	0
20	Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. Journal of Allergy and Clinical Immunology, 2022, 149, 1855-1865.	2.9	19
21	Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?. Journal of Allergy and Clinical Immunology, 2022, 149, 1866-1874.	2.9	18
22	KIT as a master regulator of the mast cell lineage. Journal of Allergy and Clinical Immunology, 2022, 149, 1845-1854.	2.9	28
23	Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?. Journal of Allergy and Clinical Immunology, 2022, 149, 1912-1918.	2.9	17
24	Massive release of TH2 cytokines induced a cytokine storm during a severe mast cell activation event in a patient with indolent systemic mastocytosis. Journal of Allergy and Clinical Immunology, 2022, 150, 406-414.e16.	2.9	3
25	CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells. Cancers, 2022, 14, 3070.	3.7	0
26	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
27	<scp>BRD4</scp> degradation blocks expression of <scp>MYC</scp> and multiple forms of stem cell resistance in Ph⁺ chronic myeloid leukemia. American Journal of Hematology, 2022, 97, 1215-1225.	4.1	14
28	Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. Leukemia, 2022, 36, 2108-2120.	7.2	22
29	Hereditary β -tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Blood, 2021, 137, 238-247.	1.4	113
30	<i>In vitro</i> effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells. Veterinary Medicine and Science, 2021, 7, 57-68.	1.6	6
31	Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. Expert Opinion on Biological Therapy, 2021, 21, 487-498.	3.1	7
32	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. International Journal of Laboratory Hematology, 2021, 43, e19-e25.	1.3	6
33	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. Theranostics, 2021, 11, 292-303.	10.0	26
34	Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis. International Journal of Molecular Sciences, 2021, 22, 411.	4.1	21
35	Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematology, the, 2021, 8, e135-e148.	4.6	32
36	A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders. International Journal of Molecular Sciences, 2021, 22, 1454.	4.1	8

#	ARTICLE	IF	CITATIONS
37	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. HemaSphere, 2021, 5, e536.	2.7	11
38	Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond. International Journal of Molecular Sciences, 2021, 22, 2458.	4.1	23
39	Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021. International Journal of Molecular Sciences, 2021, 22, 2586.	4.1	38
40	Physiology and pathology of eosinophils: Recent developments. Scandinavian Journal of Immunology, 2021, 93, e13032.	2.7	4
41	Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival. European Journal of Haematology, 2021, 106, 627-633.	2.2	3
42	Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. Lancet Haematology, 2021, 8, e194-e204.	4.6	39
43	Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis. International Journal of Molecular Sciences, 2021, 22, 2684.	4.1	23
44	Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis. International Journal of Molecular Sciences, 2021, 22, 2964.	4.1	6
45	Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. Leukemia, 2021, 35, 3176-3187.	7.2	8
46	Impact of <i>PPM1D</i> mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. American Journal of Hematology, 2021, 96, E207-E210.	4.1	2
47	Metabolome and lipidome derangements during a severe mast cell activation event in a patient with indolent systemic mastocytosis. Journal of Allergy and Clinical Immunology, 2021, 148, 1533-1544.	2.9	4
48	Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis. Blood, 2021, 137, 2070-2084.	1.4	21
49	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1705-1712.e4.	3.8	13
50	Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter. Blood, 2021, 138, 1345-1358.	1.4	12
51	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Advances, 2021, 5, 2481-2489.	5.2	25
52	COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2083-2086.	3.8	16
53	Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms. American Journal of Hematology, 2021, 96, 719-726.	4.1	1
54	Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity. Seminars in Immunopathology, 2021, 43, 423-438.	6.1	32

#	ARTICLE	IF	CITATIONS
55	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. <i>Nature Communications</i> , 2021, 12, 2901.	12.8	44
56	Mastocytosis, MCAS, and Related Disordersâ€”Diagnosis, Classification, and Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5024.	4.1	2
57	Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia. <i>European Journal of Haematology</i> , 2021, 107, 265-274.	2.2	10
58	Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (<i>JAK2</i>) V617F and KIT proto-oncogene, receptor tyrosine kinase (<i>KIT</i>) D816V mutations. <i>British Journal of Haematology</i> , 2021, 194, 344-354.	2.5	10
59	Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3918-3928.	3.8	33
60	COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2139-2144.	3.8	31
61	Case report of a clinically indolent but morphologically high-grade cutaneous mast cell tumor in an adult: atypical cutaneous mastocytoma or mast cell sarcoma?. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 1404-1409.	1.3	2
62	Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1719-1727.	0.7	14
63	A <i>STAT5B</i> - <i>CD9</i> axis determines self-renewal in hematopoietic and leukemic stem cells. <i>Blood</i> , 2021, 138, 2347-2359.	1.4	23
64	<i>TET2</i> and <i>DNMT3A</i> Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. <i>Cancer Research</i> , 2021, 81, 5089-5101.	0.9	25
65	Culturing cells with mast cell phenotype and function: Comparison of peripheral blood and bone marrow as a source.. <i>Journal of Immunological Methods</i> , 2021, 495, 113061.	1.4	6
66	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. <i>HemaSphere</i> , 2021, 5, e646.	2.7	128
67	Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. <i>Neoplasia</i> , 2021, 23, 1183-1191.	5.3	1
68	Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 530-545.	1.4	2
69	Impact of gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes. <i>American Journal of Cancer Research</i> , 2021, 11, 955-967.	1.4	0
70	Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing -compound mutations. <i>American Journal of Cancer Research</i> , 2021, 11, 4470-4484.	1.4	2
71	Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance. <i>Blood</i> , 2021, 138, 1481-1481.	1.4	6
72	Forest land tax reductions â€” an effective payment for forest ecosystem services in Slovakia?. <i>Central European Forestry Journal</i> , 2021, 67, 167-176.	0.8	3

#	ARTICLE	IF	CITATIONS
73	Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. <i>Nature Communications</i> , 2021, 12, 7190.	12.8	7
74	Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. <i>Frontiers in Veterinary Science</i> , 2021, 8, 755258.	2.2	16
75	Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 6181.	3.7	1
76	PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph+ chronic myeloid leukemia.. <i>American Journal of Cancer Research</i> , 2021, 11, 6042-6059.	1.4	0
77	High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. <i>Haematologica</i> , 2020, 105, 435-447.	3.5	27
78	Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis. <i>Haematologica</i> , 2020, 105, 366-374.	3.5	21
79	Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms. <i>Seminars in Cancer Biology</i> , 2020, 60, 191-201.	9.6	15
80	New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. <i>Leukemia and Lymphoma</i> , 2020, 61, 1075-1083.	1.3	11
81	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. <i>Leukemia</i> , 2020, 34, 1090-1101.	7.2	34
82	Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101137.	1.7	11
83	TGF β 2R-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. <i>Cell Reports</i> , 2020, 33, 108221.	6.4	18
84	Delineation of target expression profiles in CD34+/CD38 α^{\sim} and CD34+/CD38+ stem and progenitor cells in AML and CML. <i>Blood Advances</i> , 2020, 4, 5118-5132.	5.2	62
85	Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype. <i>Cancers</i> , 2020, 12, 1891.	3.7	3
86	Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues. <i>Stem Cells Translational Medicine</i> , 2020, 9, 1331-1343.	3.3	11
87	Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9030.	4.1	56
88	Switching From High-dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report. <i>HemaSphere</i> , 2020, 4, e455.	2.7	4
89	Results from a Genome-Wide Association Study (GWAS) in Mastocytosis Reveal New Gene Polymorphisms Associated with WHO Subgroups. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5506.	4.1	10
90	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020, 26, 1549-1556.	30.7	372

#	ARTICLE	IF	CITATIONS
91	Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology. <i>Journal of Personalized Medicine</i> , 2020, 10, 94.	2.5	12
92	Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6057.	4.1	5
93	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. <i>Theranostics</i> , 2020, 10, 10743-10768.	10.0	107
94	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. <i>Blood</i> , 2020, 136, 698-714.	1.4	28
95	Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3121-3127.e1.	3.8	28
96	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 300-306.	2.9	23
97	Microarray-Based Detection of Allergen-Reactive IgE in Patients with Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2761-2768.e16.	3.8	8
98	Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL. <i>Cells</i> , 2020, 9, 1484.	4.1	7
99	Searching for Pareto Fronts for Forest Stand Wind Stability by Incorporating Timber and Biodiversity Values. <i>Forests</i> , 2020, 11, 583.	2.1	15
100	A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 415-422.	1.9	0
101	Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 356-366.e4.	2.9	42
102	Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells. <i>Pharmacological Research</i> , 2020, 158, 104682.	7.1	20
103	Comparison of <i>BCR-ABL1</i> quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1214-1222.	2.3	1
104	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1927-1938.	5.7	47
105	An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 945-951.	2.5	14
106	Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia—A Retrospective Analysis in 337 Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3025.	4.1	11
107	KIT D816V and the cytokine storm in mastocytosis: production and role of interleukin-6. <i>Haematologica</i> , 2020, 105, 5-6.	3.5	14
108	STAT5 is Expressed in CD34+/CD38 ⁺ Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1021.	3.7	12

#	ARTICLE	IF	CITATIONS
109	miRNome profiling of LSC-enriched CD34+CD38 ⁺ CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool. <i>Frontiers in Pharmacology</i> , 2020, 11, 612573.	3.5	9
110	Overexpression of PD-L1 Correlates with JAK2-V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN. <i>Blood</i> , 2020, 136, 24-24.	1.4	3
111	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. <i>Blood</i> , 2020, 136, 2-4.	1.4	1
112	CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. <i>Blood</i> , 2020, 136, 387-400.	1.4	46
113	History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis. , 2020, , 287-299.		0
114	Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells. <i>Blood</i> , 2020, 136, 40-41.	1.4	0
115	Phenotyping of Disease-Initiating CD34+/CD38 ⁺ Stem Cells in BCR-ABL1 ⁺ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens. <i>Blood</i> , 2020, 136, 53-53.	1.4	0
116	<i>TET2</i> and <i>DNMT3A</i> Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. <i>Blood</i> , 2020, 136, 4-4.	1.4	1
117	ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications. <i>Pathobiology</i> , 2019, 86, 30-38.	3.8	71
118	Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms. <i>Veterinary and Comparative Oncology</i> , 2019, 17, 1-10.	1.8	18
119	The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML). <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 410-418.	1.9	18
120	Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells. <i>Veterinary and Comparative Oncology</i> , 2019, 17, 553-561.	1.8	13
121	Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. <i>International Archives of Allergy and Immunology</i> , 2019, 180, 44-51.	2.1	87
122	A kinase-independent role for CDK8 in BCR-ABL1+ leukemia. <i>Nature Communications</i> , 2019, 10, 4741.	12.8	33
123	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. <i>Lancet Haematology</i> , 2019, 6, e638-e649.	4.6	101
124	Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4233.	4.1	44
125	MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2019, 37, 2846-2856.	1.6	82
126	Twins with different personalities: STAT5B ⁺ but not STAT5A ⁺ has a key role in BCR/ABL-induced leukemia. <i>Leukemia</i> , 2019, 33, 1583-1597.	7.2	40

#	ARTICLE	IF	CITATIONS
127	CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex. <i>Leukemia</i> , 2019, 33, 1608-1619.	7.2	19
128	Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2976.	4.1	64
129	A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2461-2478.	5.7	32
130	Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. <i>Hematological Oncology</i> , 2019, 37, 240-252.	1.7	8
131	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. <i>Haematologica</i> , 2019, 104, 1935-1949.	3.5	93
132	Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from Fiction. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1109-1114.	3.8	34
133	Identification of a leukemia-initiating stem cell in human mast cell leukemia. <i>Leukemia</i> , 2019, 33, 2673-2684.	7.2	21
134	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1125-1133.e1.	3.8	150
135	Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML. <i>International Journal of Molecular Sciences</i> , 2019, 20, 789.	4.1	50
136	CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. <i>EBioMedicine</i> , 2019, 50, 111-121.	6.1	14
137	Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2019, 77, 8-13.	0.8	0
138	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 81-87.	3.8	42
139	Massive release of the histamine-degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 583-593.	5.7	32
140	A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML. <i>Leukemia Research</i> , 2019, 78, 36-44.	0.8	3
141	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. <i>Leukemia</i> , 2019, 33, 1124-1134.	7.2	29
142	CDK6 coordinates JAK2V617F mutant MPN via NF- κ B and apoptotic networks. <i>Blood</i> , 2019, 133, 1677-1690.	1.4	29
143	The Mastocytosis Society Survey on Mast Cell Disorders: Part 2 "Patient Clinical Experiences and Beyond. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1157-1165.e6.	3.8	16
144	Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1098-1101.	1.3	12

#	ARTICLE	IF	CITATIONS
145	Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2019, 134, 4223-4223.	1.4	1
146	Forest modelling and visualisation â€“ state of the art and perspectives. <i>Central European Forestry Journal</i> , 2019, 65, 147-165.	0.8	7
147	Mastozytosen. , 2019, , 95-113.		0
148	Cover Image, Volume 16, Issue 1. <i>Veterinary and Comparative Oncology</i> , 2018, 16, i.	1.8	0
149	The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. <i>Haematologica</i> , 2018, 103, 799-809.	3.5	30
150	Adapting forest management to climate change in Europe: Linking perceptions to adaptive responses. <i>Forest Policy and Economics</i> , 2018, 90, 22-30.	3.4	87
151	Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 252-259.	2.8	48
152	Pharmacologic inhibition of STAT5 in acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 1135-1146.	7.2	112
153	Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform. <i>Expert Review of Hematology</i> , 2018, 11, 109-116.	2.2	3
154	Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. <i>Leukemia</i> , 2018, 32, 1713-1726.	7.2	166
155	Major response of PNH to an AML chemotherapy protocol. <i>Annals of Hematology</i> , 2018, 97, 1487-1488.	1.8	1
156	The <sc>JAK2</sc>/<sc>STAT5</sc> signaling pathway as a potential therapeutic target in canine mastocytoma. <i>Veterinary and Comparative Oncology</i> , 2018, 16, 55-68.	1.8	19
157	The <sc>JAK</sc>2 blocker <sc>TG</sc>101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2018, 181, 137-139.	2.5	3
158	Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia. <i>Experimental Hematology</i> , 2018, 57, 50-59.e6.	0.4	16
159	BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib. <i>Haematologica</i> , 2018, 103, e10-e12.	3.5	26
160	A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) â€“ AGMT_CMML-1. <i>Leukemia and Lymphoma</i> , 2018, 59, 1121-1126.	1.3	5
161	Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis. <i>Clinical Chemistry</i> , 2018, 64, 547-555.	3.2	49
162	Anemia at older age: etiologies, clinical implications, and management. <i>Blood</i> , 2018, 131, 505-514.	1.4	266

#	ARTICLE	IF	CITATIONS
163	Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 45-57.	3.4	19
164	High Precision Individual Tree Diameter and Perimeter Estimation from Close-Range Photogrammetry. <i>Forests</i> , 2018, 9, 696.	2.1	34
165	Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3987.	4.1	13
166	Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 547-556.	2.8	3
167	The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. <i>Future Oncology</i> , 2018, 14, 2713-2723.	2.4	9
168	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. <i>Leukemia Research</i> , 2018, 73, 51-57.	0.8	20
169	Variability of PD-L1 expression in mastocytosis. <i>Blood Advances</i> , 2018, 2, 189-199.	5.2	10
170	Phenotyping and Target Expression Profiling of CD34+/CD38 ⁺ and CD34+/CD38 ⁻ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia. <i>Neoplasia</i> , 2018, 20, 632-642.	5.3	32
171	MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. <i>Nature Communications</i> , 2018, 9, 1983.	12.8	43
172	Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. <i>Blood</i> , 2018, 132, 67-77.	1.4	54
173	Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. <i>Haematologica</i> , 2018, 103, 1593-1603.	3.5	49
174	Eosinophilia, Eosinophil-Associated Diseases, Eosinophilic Leukemias, and the Hypereosinophilic Syndromes. , 2018, , 1151-1169.		0
175	Mast Cells and Mastocytosis. , 2018, , 1170-1186.		1
176	Evaluation of Close-Range Photogrammetry Image Collection Methods for Estimating Tree Diameters. <i>ISPRS International Journal of Geo-Information</i> , 2018, 7, 93.	2.9	76
177	Preclinical human models and emerging therapeutics for advanced systemic mastocytosis. <i>Haematologica</i> , 2018, 103, 1760-1771.	3.5	18
178	Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 517-529.	1.9	3
179	Mast cell activation syndrome: Importance of consensus criteria and call for research. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1008-1010.	2.9	27
180	The underestimated role of basophils in Ph ⁺ chronic myeloid leukaemia. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13000.	3.4	25

#	ARTICLE	IF	CITATIONS
181	CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. <i>Blood</i> , 2018, 132, 1936-1950.	1.4	18
182	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (Iâ€¢-CBF) Tj ETQg 0 0 rgBT /Overlo	2.8	17
183	Molecular Aspects of Allergens and Allergy. <i>Advances in Immunology</i> , 2018, 138, 195-256.	2.2	81
184	Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. <i>Cell Reports</i> , 2018, 23, 3127-3136.	6.4	68
185	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. <i>Blood</i> , 2018, 132, 694-706.	1.4	132
186	Thinning trainer based on forest-growth model, virtual reality and computer-aided virtual environment. <i>Environmental Modelling and Software</i> , 2018, 100, 11-23.	4.5	24
187	BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph+ CML. <i>Blood</i> , 2018, 132, 1722-1722.	1.4	5
188	A New Prognostic Score for Advanced Systemic Mastocytosis Based on Clinical and Genetic Characteristics of 210 Consecutive Patients. <i>Blood</i> , 2018, 132, 349-349.	1.4	1
189	The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest. <i>Blood</i> , 2018, 132, 1363-1363.	1.4	2
190	Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells. <i>Oncotarget</i> , 2018, 9, 26491-26506.	1.8	23
191	Extracorporeal IgE Immunoabsorption in Allergic Asthma: Safety and Efficacy. <i>EBioMedicine</i> , 2017, 17, 119-133.	6.1	23
192	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017, 77, 1261-1270.	0.9	210
193	The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. <i>Haematologica</i> , 2017, 102, 1035-1043.	3.5	84
194	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. <i>Cell Reports</i> , 2017, 18, 2162-2174.	6.4	244
195	Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. <i>Blood</i> , 2017, 130, 137-145.	1.4	97
196	Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. <i>Leukemia Research</i> , 2017, 59, 47-54.	0.8	58
197	Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications. <i>Experimental Hematology</i> , 2017, 51, 17-24.	0.4	31
198	Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 175-184.	1.6	36

#	ARTICLE	IF	CITATIONS
199	Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1519-1529.	3.5	36
200	Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. <i>Blood</i> , 2017, 129, 1420-1427.	1.4	520
201	Quantification of human diamine oxidase. <i>Clinical Biochemistry</i> , 2017, 50, 444-451.	1.9	29
202	CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. <i>Blood</i> , 2017, 129, 371-382.	1.4	24
203	First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. <i>Blood</i> , 2017, 130, 2499-2503.	1.4	59
204	Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥ 60 years. <i>American Journal of Hematology</i> , 2017, 92, E567-E574.	4.1	9
205	Peripheral arterial disease outcomes and association with suPAR: A bridge to myeloid precursors or mast cells or both?. <i>Atherosclerosis</i> , 2017, 264, 77-78.	0.8	0
206	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. <i>EBioMedicine</i> , 2017, 26, 17-24.	6.1	24
207	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. <i>Lancet Haematology</i> , 2017, 4, e595-e606.	4.6	130
208	Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 404-410.	1.9	4
209	Clototoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model. <i>Frontiers in Pharmacology</i> , 2017, 8, 319.	3.5	23
210	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 837.	4.1	19
211	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. <i>Oncotarget</i> , 2017, 8, 73483-73500.	1.8	153
212	STAT5BN642H is a driver mutation for T cell neoplasia. <i>Journal of Clinical Investigation</i> , 2017, 128, 387-401.	8.2	57
213	Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. <i>Journal of Clinical Investigation</i> , 2017, 127, 2392-2406.	8.2	64
214	Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. <i>Oncotarget</i> , 2017, 8, 11600-11613.	1.8	43
215	TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. <i>Oncotarget</i> , 2017, 8, 23061-23072.	1.8	13
216	The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells. <i>Oncotarget</i> , 2017, 8, 67709-67722.	1.8	13

#	ARTICLE	IF	CITATIONS
217	Multidisciplinary Management of Mastocytosis: Nordic Expert Group Consensus. <i>Acta Dermato-Venereologica</i> , 2016, 96, 602-612.	1.3	21
218	Molecular, Structural and Immunological Characterization of Der p 18, a Chitinase-Like House Dust Mite Allergen. <i>PLoS ONE</i> , 2016, 11, e0160641.	2.5	30
219	Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis—Masters of Survival and Clonality?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1009.	4.1	39
220	Allogeneic hematopoietic cell transplantation in systemic mastocytosis: is there a high risk for veno-occlusive disease?. <i>European Journal of Haematology</i> , 2016, 96, 655-657.	2.2	7
221	<i>In vitro</i> and <i>in vivo</i> effects of JAK2 inhibition in chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2016, 97, 562-567.	2.2	13
222	Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?. <i>Haematologica</i> , 2016, 101, e492-e492.	3.5	1
223	The myeloma stem cell concept, revisited: from phenomenology to operational terms. <i>Haematologica</i> , 2016, 101, 1451-1459.	3.5	55
224	Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1831-1838.	1.3	23
225	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76
226	Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. <i>Blood</i> , 2016, 127, 2131-2143.	1.4	32
227	Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. <i>Blood</i> , 2016, 127, 2890-2902.	1.4	96
228	Time-dependent changes in mortality and transformation risk in MDS. <i>Blood</i> , 2016, 128, 902-910.	1.4	140
229	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. <i>Haematologica</i> , 2016, 101, 1133-1143.	3.5	60
230	Functional characterization, localization, and inhibitor sensitivity of the TPR-FCFR1 fusion in 8p11 myeloproliferative syndrome. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 60-68.	2.8	13
231	Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. <i>European Journal of Clinical Investigation</i> , 2016, 46, 392-397.	3.4	21
232	Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. <i>EBioMedicine</i> , 2016, 11, 43-57.	6.1	109
233	Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy. <i>American Journal of Hematology</i> , 2016, 91, 1239-1245.	4.1	10
234	Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. <i>Blood</i> , 2016, 128, 2096-2097.	1.4	46

#	ARTICLE	IF	CITATIONS
235	Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine. <i>Journal of Innate Immunity</i> , 2016, 8, 111-120.	3.8	249
236	Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. <i>New England Journal of Medicine</i> , 2016, 374, 2530-2541.	27.0	383
237	Probability of remaining in unsustained complete remission after steroid therapy withdrawal in patients with primary warm-antibody reactive autoimmune hemolytic anemia. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 234-237.	1.9	12
238	Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. <i>Clinical Cancer Research</i> , 2016, 22, 2051-2061.	7.0	52
239	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 35-45.	2.9	289
240	Frequent occurrence of T _H 2-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 601-609.e8.	2.9	37
241	Ponatinib Exerts Multiple Effects on Vascular Endothelial Cells: Possible Mechanisms and Explanations for the Adverse Vascular Events Seen in CML Patients Treated with Ponatinib. <i>Blood</i> , 2016, 128, 1883-1883.	1.4	9
242	Mast Cell Leukemia: Clinical Heterogeneity, Molecular Aberrations, Treatment Responses, Survival, and Prognostic Factors. <i>Blood</i> , 2016, 128, 3109-3109.	1.4	2
243	Evaluation of Cell Surface Markers and Targets in Leukemic Stem Cells (LSC) Reveals Distinct Expression Profiles, Unique Drug Effects, and Specific Checkpoint Regulation in AML LSC and CML LSC. <i>Blood</i> , 2016, 128, 4234-4234.	1.4	2
244	Impact of Molecular Markers on Response and Resistance in Midostaurin-Treated Patients with Advanced Systemic Mastocytosis. <i>Blood</i> , 2016, 128, 945-945.	1.4	3
245	Incidence and Prognostic Impact of Cytogenetics in Combination with Molecular Aberrations in Patients with Systemic Mastocytosis. <i>Blood</i> , 2016, 128, 947-947.	1.4	2
246	Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56 ^{bright} NK cell subpopulations in patients with acute myeloid leukemia and supports their activation. <i>Oncotarget</i> , 2016, 7, 46466-46481.	1.8	19
247	Evaluation of <i>in vitro</i> effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma. <i>Oncotarget</i> , 2016, 7, 65627-65642.	1.8	6
248	Transposon-mediated generation of <i>BCR-ABL1</i> -expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors. <i>Oncotarget</i> , 2016, 7, 78083-78094.	1.8	12
249	Quantitative assessment of the CD26 ⁺ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects. <i>Oncotarget</i> , 2016, 7, 33016-33024.	1.8	31
250	The Genomic and Transcriptomic Landscape of Systemic Mastocytosis. <i>Blood</i> , 2016, 128, 3136-3136.	1.4	1
251	Diagnosis and management of mastocytosis: an emerging challenge in applied hematology. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 98-105.	2.5	39
252	Characterization and targeting of neoplastic stem cells in Ph+chronic myeloid leukemia. <i>International Journal of Hematologic Oncology</i> , 2015, 4, 151-165.	1.6	1

#	ARTICLE	IF	CITATIONS
253	All systems red. American Journal of Hematology, 2015, 90, 356-360.	4.1	1
254	Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. International Journal of Cancer, 2015, 136, 2078-2090.	5.1	60
255	Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood, 2015, 125, 901-906.	1.4	239
256	Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. Blood, 2015, 126, 2832-2841.	1.4	47
257	Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. Haematologica, 2015, 100, 205-213.	3.5	20
258	Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group. Genes Chromosomes and Cancer, 2015, 54, 809-817.	2.8	8
259	cFinder: definition and quantification of multiple haplotypes in a mixed sample. BMC Research Notes, 2015, 8, 422.	1.4	8
260	Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms. Mediators of Inflammation, 2015, 2015, 1-17.	3.0	40
261	Chronic mast cell leukemia: A novel leukemia-variant with distinct morphological and clinical features. Leukemia Research, 2015, 39, 1-5.	0.8	90
262	Novel Targeted Therapies for Eosinophil-Associated Diseases and Allergy. Annual Review of Pharmacology and Toxicology, 2015, 55, 633-656.	9.4	47
263	Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. Annals of Hematology, 2015, 94, 223-231.	1.8	20
264	Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. European Journal of Haematology, 2015, 94, 474-490.	2.2	64
265	Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. Journal of Allergy and Clinical Immunology, 2015, 135, 1207-1217.e11.	2.9	115
266	Mast Cells, Mastocytosis, and Related Disorders. New England Journal of Medicine, 2015, 373, 163-172.	27.0	402
267	10th anniversary of the Austrian MDS Platform: aims and ongoing projects. Wiener Klinische Wochenschrift, 2015, 127, 12-15.	1.9	1
268	Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. Journal of Hematology and Oncology, 2015, 8, 16.	17.0	80
269	Dasatinib-induced immunosuppression and recurrent respiratory tract infections. Leukemia and Lymphoma, 2015, 56, 2484-2485.	1.3	7
270	Mast Cells, Mastocytosis, and Related Disorders. New England Journal of Medicine, 2015, 373, 1884-1886.	27.0	39

#	ARTICLE	IF	CITATIONS
271	Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1581-1590.e3.	2.9	61
272	Antibody conjugates bispecific for intercellular adhesion molecule 1 and allergen prevent migration of allergens through respiratory epithelial cell layers. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 490-493.e11.	2.9	8
273	Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. <i>Nature</i> , 2015, 525, 543-547.	27.8	414
274	Molecular Evolution of Hypoallergenic Hybrid Proteins for Vaccination against Grass Pollen Allergy. <i>Journal of Immunology</i> , 2015, 194, 4008-4018.	0.8	23
275	Autocrine fibroblast growth factor 18 signaling mediates Wnt-dependent stimulation of CD44-positive human colorectal adenoma cells. <i>Molecular Carcinogenesis</i> , 2015, 54, 789-799.	2.7	18
276	Der p 11 Is a Major Allergen for House Dust Mite-Allergic Patients Suffering from Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2015, 135, 102-109.	0.7	93
277	Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 2879-2879.	1.4	1
278	Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis. <i>Blood</i> , 2015, 126, 4085-4085.	1.4	2
279	An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015, 126, 609-609.	1.4	5
280	Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 3071-3084.	1.8	50
281	Paul Ehrlich (1854-1915) and the Birth of Molecular Medicine. , 2015, 12, .		0
282	Identification of the Epigenetic Reader BRD4 As a Novel Potential Target in Ph+ CML. <i>Blood</i> , 2015, 126, 1571-1571.	1.4	0
283	Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML. <i>American Journal of Cancer Research</i> , 2015, 5, 354-62.	1.4	5
284	Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells. <i>American Journal of Cancer Research</i> , 2015, 5, 560-74.	1.4	7
285	Phenotyping of Human Melanoma Cells Reveals a Unique Composition of Receptor Targets and a Subpopulation Co-Expressing ErbB4, EPO-R and NGF-R. <i>PLoS ONE</i> , 2014, 9, e84417.	2.5	15
286	Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML. <i>Clinical Cancer Research</i> , 2014, 20, 3589-3602.	7.0	26
287	Mast cell leukemia: a review. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 395-405.	1.6	5
288	Myelomastocytic leukemia: histopathological features, diagnostic criteria and differential diagnosis. <i>Expert Review of Hematology</i> , 2014, 7, 431-437.	2.2	23

#	ARTICLE	IF	CITATIONS
289	Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. <i>Haematologica</i> , 2014, 99, 417-429.	3.5	50
290	BRD4: A BET(ter) target for the treatment of AML?. <i>Cell Cycle</i> , 2014, 13, 689-690.	2.6	25
291	Familial hypertryptasemia with associated mast cell activation syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1448-1450.e3.	2.9	44
292	DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1239-1245.	3.4	51
293	Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. <i>Leukemia Research</i> , 2014, 38, 475-483.	0.8	59
294	Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 315-321.	1.9	30
295	The Mastocytosis Society Survey on Mast Cell Disorders: Patient Experiences and Perceptions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 70-76.	3.8	107
296	Evaluation of treatment responses and colony-forming progenitor cells in 50 patients with aplastic anemia after immunosuppressive therapy or hematopoietic stem cell transplantation: a single-center experience. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 119-125.	1.9	7
297	Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 23-29.	1.9	3
298	Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes. <i>Journal of Geriatric Oncology</i> , 2014, 5, 299-306.	1.0	24
299	The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 1-16.	4.4	24
300	Clofarabine/cyclophosphamide for debulking before stem cell transplantation. <i>European Journal of Clinical Investigation</i> , 2014, 44, 775-783.	3.4	3
301	The serum tryptase test: an emerging robust biomarker in clinical hematology. <i>Expert Review of Hematology</i> , 2014, 7, 683-690.	2.2	65
302	Conversion of Der p 23, a New Major House Dust Mite Allergen, into a Hypoallergenic Vaccine. <i>Journal of Immunology</i> , 2014, 192, 4867-4875.	0.8	69
303	Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 376-382.	1.9	17
304	Diagnosis and Treatment of Anaphylaxis in Patients with Mastocytosis. <i>Current Treatment Options in Allergy</i> , 2014, 1, 247-261.	2.2	4
305	CD52 is a molecular target in advanced systemic mastocytosis. <i>FASEB Journal</i> , 2014, 28, 3540-3551.	0.5	24
306	Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3264-3274.	1.6	146

#	ARTICLE	IF	CITATIONS
307	Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 836-845.e11.	2.9	36
308	Diagnostic Criteria and Classification of Mastocytosis in 2014. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 207-218.	1.9	89
309	FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. <i>Leukemia Research Reports</i> , 2014, 3, 8-13.	0.4	12
310	Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFR α . <i>Experimental Hematology</i> , 2014, 42, 282-293.e4.	0.4	41
311	A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. <i>Blood</i> , 2014, 124, 111-120.	1.4	80
312	Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. <i>Blood</i> , 2014, 123, 3951-3962.	1.4	189
313	Targeting the JAK2-STAT5 pathway in CML. <i>Blood</i> , 2014, 124, 1386-1388.	1.4	25
314	Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML. <i>Blood</i> , 2014, 124, 1800-1800.	1.4	5
315	Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia. <i>Blood</i> , 2014, 124, 1881-1881.	1.4	2
316	Azacitidine in Patients with Treatment-Related Acute Myeloid Leukemia: Retrospective Analysis of the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 2284-2284.	1.4	2
317	Incidence of Intensive Care Unit Admission, Outcome, and Post Intensive Care Survival in Patients with Acute Lymphocytic Leukemia or Burkitt Lymphoma. <i>Blood</i> , 2014, 124, 2633-2633.	1.4	1
318	A Phase I Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukaemia (CMML) â€” AGMT_CMML 1. <i>Blood</i> , 2014, 124, 3268-3268.	1.4	1
319	Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 3681-3681.	1.4	3
320	Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome. <i>Blood</i> , 2014, 124, 3683-3683.	1.4	1
321	A Novel Fusion Gene NDEL1-Pdgfrb in a Patient with JMML with a New Variant of TKI-Resistant Mutation in the Kinase Domain of PDGFR β . <i>Blood</i> , 2014, 124, 613-613.	1.4	5
322	Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. <i>Blood</i> , 2014, 124, 636-636.	1.4	15
323	Identification of a Neoplastic Stem Cell in Human Mast Cell Leukemia. <i>Blood</i> , 2014, 124, 817-817.	1.4	6
324	Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 943-943.	1.4	2

#	ARTICLE	IF	CITATIONS
325	Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes. <i>Blood</i> , 2014, 124, 955-955.	1.4	26
326	Mast cells and mast cell growth factor: possible role in auricular thrombosis. <i>Biomedical Reviews</i> , 2014, 4, 29.	0.6	2
327	Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia. <i>Oncotarget</i> , 2014, 5, 1198-1211.	1.8	19
328	Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia. <i>Oncotarget</i> , 2014, 5, 9564-9576.	1.8	39
329	Next Generation Sequencing Identifies DNA Methylation Patterns Indicative of Disease Progression in Ph+ CML. <i>Blood</i> , 2014, 124, 4526-4526.	1.4	0
330	Identification of CAR As a Novel Mediator of Erythroid Differentiation and Migration That Is Specifically Downregulated in Erythropoietic Progenitor Cells in Patients with MDS. <i>Blood</i> , 2014, 124, 1570-1570.	1.4	14
331	Molecular Profiling of Myeloid Progenitor Cells in Multi-Mutated Advanced Systemic Mastocytosis Identifies KIT D816V As a Distinct and Late Event. <i>Blood</i> , 2014, 124, 3216-3216.	1.4	0
332	Gene Expression and Mutation Analysis (GEMA) â€“Guided Precision Medicine Targeting PARP1 to Induce Synthetic Lethality in DNA-PK â€“Deficient Quiescent and BRCA-Deficient Proliferating Leukemia Stem and Progenitor Cells. <i>Blood</i> , 2014, 124, 480-480.	1.4	0
333	Maintenance with Histamine and IL-2 Induces a Marked Expansion of Activated CD56bright NK Cells in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 1422-1422.	1.4	0
334	Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT. <i>American Journal of Blood Research</i> , 2014, 4, 93-100.	0.6	11
335	The Austrian Competence Network on Mastocytosis (AUCNM): a partner and part of the European ECNM network. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 114-118.	0.5	0
336	Characterization of mutants of a highly cross-reactive calcium-binding protein from Brassica pollen for allergen-specific immunotherapy. <i>Immunobiology</i> , 2013, 218, 1155-1165.	1.9	5
337	Overexpression of primary microRNA 221/222 in acute myeloid leukemia. <i>BMC Cancer</i> , 2013, 13, 364.	2.6	45
338	Endogenous Erythroid Colony Formation in Chronic Myeloid Leukemia: A Recurrent Finding Associated with Persistent Minimal Residual Disease Under Imatinib. <i>Stem Cells and Development</i> , 2013, 22, 3043-3051.	2.1	1
339	Comprehensive mutational profiling in advanced systemic mastocytosis. <i>Blood</i> , 2013, 122, 2460-2466.	1.4	222
340	Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: A multicenter retrospective study. <i>Leukemia Research</i> , 2013, 37, 862-867.	0.8	12
341	Heterogeneity of Neoplastic Stem Cells: Theoretical, Functional, and Clinical Implications. <i>Cancer Research</i> , 2013, 73, 1037-1045.	0.9	55
342	Comparative analysis of <sc>IL</sc>6 and <sc>IL</sc>6 receptor gene polymorphisms in mastocytosis. <i>British Journal of Haematology</i> , 2013, 160, 216-219.	2.5	13

#	ARTICLE	IF	CITATIONS
343	Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?. <i>American Journal of Hematology</i> , 2013, 88, 533-534.	4.1	7
344	Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. <i>Leukemia and Lymphoma</i> , 2013, 54, 472-475.	1.3	66
345	A Nonallergenic Birch Pollen Allergy Vaccine Consisting of Hepatitis PreS-Fused Bet v 1 Peptides Focuses Blocking IgG toward IgE Epitopes and Shifts Immune Responses to a Tolerogenic and Th1 Phenotype. <i>Journal of Immunology</i> , 2013, 190, 3068-3078.	0.8	57
346	The impact of molecular targets in cancer drug development: major hurdles and future strategies. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 23-34.	3.1	19
347	Gliotoxin is a potent NOTCH2 transactivation inhibitor and efficiently induces apoptosis in chronic lymphocytic leukaemia (CLL) cells. <i>British Journal of Haematology</i> , 2013, 160, 618-629.	2.5	34
348	A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the polo-like kinase inhibitor B-2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013, 163, 214-222.	2.5	36
349	Proposed score for survival of patients with myelodysplastic syndromes. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1120-1128.	3.4	12
350	Anti-Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) differentially regulate apoptosis in normal and neoplastic human basophils. <i>Leukemia and Lymphoma</i> , 2013, 54, 835-842.	1.3	13
351	Identification of Der p 23, a Peritrophin-like Protein, as a New Major Dermatophagoides pteronyssinus Allergen Associated with the Peritrophic Matrix of Mite Fecal Pellets. <i>Journal of Immunology</i> , 2013, 190, 3059-3067.	0.8	177
352	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013, 121, 2393-2401.	1.4	122
353	Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. <i>Haematologica</i> , 2013, 98, 1450-1457.	3.5	39
354	E- and P-Selectins Are Essential for Repopulation of Chronic Myelogenous and Chronic Eosinophilic Leukemias in a Scid Mouse Xenograft Model. <i>PLoS ONE</i> , 2013, 8, e70139.	2.5	16
355	A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL. <i>PLoS ONE</i> , 2013, 8, e77155.	2.5	15
356	The Transcription Factor MAZR Preferentially Acts as a Transcriptional Repressor in Mast Cells and Plays a Minor Role in the Regulation of Effector Functions in Response to Fc μ RI Stimulation. <i>PLoS ONE</i> , 2013, 8, e77677.	2.5	9
357	The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. <i>Journal of Leukocyte Biology</i> , 2013, 95, 95-104.	3.3	32
358	Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial. <i>Blood</i> , 2013, 122, 106-106.	1.4	6
359	Phenotyping Of Leukemic Stem Cells In Ph+ ALL and Ph- ALL Reveals Unique Profiles Of Markers and Targets In Distinct Disease Variants. <i>Blood</i> , 2013, 122, 1654-1654.	1.4	1
360	Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML. <i>Blood</i> , 2013, 122, 257-257.	1.4	41

#	ARTICLE	IF	CITATIONS
361	Oncogene-Induced DNA Repair Defects Promote PARP1-Mediated "Dual Synthetic Lethality" To Eradicate Quiescent and Proliferating Leukemia Stem and Progenitor Cells. <i>Blood</i> , 2013, 122, 810-810.	1.4	2
362	Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. <i>American Journal of Cancer Research</i> , 2013, 3, 159-72.	1.4	17
363	Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM). <i>American Journal of Blood Research</i> , 2013, 3, 174-80.	0.6	16
364	Systemic mastocytosis. , 2012, , 369-378.		0
365	Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. <i>FASEB Journal</i> , 2012, 26, 894-906.	0.5	40
366	CD34+/CD38- stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. <i>Haematologica</i> , 2012, 97, 219-226.	3.5	59
367	Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal. <i>International Archives of Allergy and Immunology</i> , 2012, 157, 215-225.	2.1	513
368	Glucocorticosteroids Rescue Basophils from Dasatinib-Augmented Immunoglobulin E-Mediated Histamine Release. <i>International Archives of Allergy and Immunology</i> , 2012, 159, 15-22.	2.1	2
369	5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. <i>Blood</i> , 2012, 119, 4242-4252.	1.4	41
370	Controversies and Open Questions in the Definitions and Classification of the Hypereosinophilic Syndromes and Eosinophilic Leukemias. <i>Seminars in Hematology</i> , 2012, 49, 171-181.	3.4	17
371	Rac2-MRC-111-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. <i>Blood</i> , 2012, 119, 4253-4263.	1.4	147
372	PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. <i>Nature Medicine</i> , 2012, 18, 1699-1704.	30.7	113
373	Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 607-612.e9.	2.9	604
374	Diagnosis, progression patterns and prognostication in mastocytosis. <i>Expert Review of Hematology</i> , 2012, 5, 261-274.	2.2	37
375	European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 807-814.	1.9	33
376	ICON: Eosinophil Disorders. <i>World Allergy Organization Journal</i> , 2012, 5, 174-181.	3.5	25
377	New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. <i>Journal of Clinical Oncology</i> , 2012, 30, 820-829.	1.6	584
378	Revised International Prognostic Scoring System for Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 2454-2465.	1.4	2,458

#	ARTICLE	IF	CITATIONS
379	Cancer stem cell definitions and terminology: the devil is in the details. <i>Nature Reviews Cancer</i> , 2012, 12, 767-775.	28.4	599
380	Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 435-443.e4.	2.9	84
381	Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. <i>Nature Chemical Biology</i> , 2012, 8, 905-912.	8.0	96
382	Severe Life-Threatening or Disabling Anaphylaxis in Patients with Systemic Mastocytosis: A Single-Center Experience. <i>International Archives of Allergy and Immunology</i> , 2012, 157, 399-405.	2.1	60
383	Identification of Basophils as a Major Source of Hepatocyte Growth Factor in Chronic Myeloid Leukemia: A Novel Mechanism of BCR-ABL1-Independent Disease Progression. <i>Neoplasia</i> , 2012, 14, 572-IN10.	5.3	45
384	Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. <i>Expert Review of Hematology</i> , 2012, 5, 157-176.	2.2	140
385	Low blood counts: immune mediated, idiopathic, or myelodysplasia. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 485-491.	2.5	42
386	STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. <i>Oncotarget</i> , 2012, 3, 1669-1687.	1.8	64
387	Monoclonal B-cell lymphocytosis (MBL) with normal lymphocyte counts is associated with decreased numbers of normal circulating B-cell subsets. <i>American Journal of Hematology</i> , 2012, 87, 721-724.	4.1	14
388	Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 370-377.	4.4	8
389	Systemic Mastocytosis Associated with Lymphoproliferative Disorders (SM-AHNMD). , 2012, , 271-279.		1
390	Low blood counts: immune mediated, idiopathic, or myelodysplasia. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 485-91.	2.5	26
391	Serum Tryptase Is a Strong Predictive Biomarker That Improves Prognostication in Ph+ Chronic Myeloid Leukemia.. <i>Blood</i> , 2012, 120, 2783-2783.	1.4	2
392	KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. <i>Blood</i> , 2012, 120, 799-799.	1.4	19
393	The PI3-Kinase/mTOR-Targeting Drug NVP-BEZ235 Inhibits Growth and IgE-Dependent Activation of Human Mast Cells and Basophils. <i>PLoS ONE</i> , 2012, 7, e29925.	2.5	24
394	Nilotinib and Imatinib Are Comparably Effective in Reducing Growth of Human Eosinophil Leukemia Cells in a Newly Established Xenograft Model. <i>PLoS ONE</i> , 2012, 7, e30567.	2.5	4
395	Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML). <i>Oncotarget</i> , 2012, 3, 1588-1599.	1.8	144
396	Identification of Campath-1 Antigen (CD52) As a Novel Therapeutic Target in Advanced Systemic Mastocytosis.. <i>Blood</i> , 2012, 120, 2866-2866.	1.4	0

#	ARTICLE	IF	CITATIONS
397	Effects of Ponatinib and Other Novel TKI On Growth, Survival, and Function of Neoplastic Eosinophils Carrying FIP1L1/Pdgfra. <i>Blood</i> , 2012, 120, 1760-1760.	1.4	0
398	Clofarabine/Cyclophosphamide (ClofCy) for Debulking refractory Acute Leukemias Prior to Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4504-4504.	1.4	0
399	Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches. <i>Leukemia and Lymphoma</i> , 2011, 52, 1435-1445.	1.3	12
400	Stable non-transforming minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia after autologous transplantation: origin from neoplastic yet "pre-leukemic" stem cells?. <i>Leukemia and Lymphoma</i> , 2011, 52, 842-848.	1.3	8
401	A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1562-1570.e6.	2.9	92
402	RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. <i>Nature</i> , 2011, 478, 524-528.	27.8	1,656
403	Identification of Oncostatin M as a STAT5-Dependent Mediator of Bone Marrow Remodeling in KIT D816V-Positive Systemic Mastocytosis. <i>American Journal of Pathology</i> , 2011, 178, 2344-2356.	3.8	36
404	Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis. <i>Cell</i> , 2011, 147, 306-319.	28.9	122
405	Improved Outcome in Patients with Chronic Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation Over the Past 25 Years: A Single-Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 133-140.	2.0	14
406	Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. <i>Vaccine</i> , 2011, 29, 2140-2148.	3.8	29
407	KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. <i>Blood</i> , 2011, 118, 1885-1898.	1.4	64
408	High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. <i>Blood</i> , 2011, 117, 3409-3420.	1.4	168
409	Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. <i>Haematologica</i> , 2011, 96, 163-166.	3.5	51
410	Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer. <i>Molecular Immunology</i> , 2011, 48, 431-441.	2.2	33
411	Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. <i>Leukemia Research</i> , 2011, 36, 1-5.	0.8	83
412	Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. <i>Leukemia and Lymphoma</i> , 2011, 52, 740-744.	1.3	64
413	Severe Peripheral Arterial Disease During Nilotinib Therapy. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1347-1348.	6.3	145
414	Developmental, Malignancy-Related, and Cross-Species Analysis of Eosinophil, Mast Cell, and Basophil Siglec-8 Expression. <i>Journal of Clinical Immunology</i> , 2011, 31, 1045-1053.	3.8	50

#	ARTICLE	IF	CITATIONS
415	The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 387-400.	2.5	52
416	Successful allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia during respiratory failure and invasive mechanical ventilation. <i>Wiener Klinische Wochenschrift</i> , 2011, 123, 354-358.	1.9	2
417	Eosinophil, basophil, and mast cell infiltrates in the bone marrow: crossing the boundaries of diagnosis. <i>Journal of Hematopathology</i> , 2011, 4, 101-111.	0.4	12
418	Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. <i>American Journal of Hematology</i> , 2011, 86, 533-539.	4.1	254
419	Second line BCR/ABK TKI-associated severe adverse events: preferential occurrence in patients with comorbidities. <i>Haematologica</i> , 2011, 96, 1395-7.	3.5	38
420	Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. <i>Modern Pathology</i> , 2011, 24, 585-595.	5.5	131
421	Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept. <i>Current Cancer Drug Targets</i> , 2011, 11, 56-71.	1.6	52
422	Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System. <i>Journal of Clinical Oncology</i> , 2011, 29, 1963-1970.	1.6	139
423	Expression of a Major Plant Allergen as Membrane-Anchored and Secreted Protein in Human Cells with Preserved T Cell and B Cell Epitopes. <i>International Archives of Allergy and Immunology</i> , 2011, 156, 259-266.	2.1	6
424	Clinical and Laboratory Parameters of Mast Cell Activation as Basis for the Formulation of Diagnostic Criteria. <i>International Archives of Allergy and Immunology</i> , 2011, 156, 119-127.	2.1	46
425	Classification and Response Criteria in Mast Cell Disorders: Time to Revise?. <i>International Archives of Allergy and Immunology</i> , 2011, 155, 306-308.	2.1	3
426	Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. <i>Haematologica</i> , 2011, 96, 672-680.	3.5	17
427	Mapping of Conformational IgE Epitopes with Peptide-Specific Monoclonal Antibodies Reveals Simultaneous Binding of Different IgE Antibodies to a Surface Patch on the Major Birch Pollen Allergen, Bet v 1. <i>Journal of Immunology</i> , 2011, 186, 5333-5344.	0.8	82
428	Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience. <i>Haematologica</i> , 2011, 96, 231-237.	3.5	116
429	The Midostaurin (PKC412) Metabolite CGP52421 Shows Little Growth-Inhibitory Activity Against Neoplastic Mast Cells but Retains Inhibitory Effects on IgE-Dependent Activation and Histamine Release. <i>Blood</i> , 2011, 118, 1417-1417.	1.4	1
430	Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML. <i>Blood</i> , 2011, 118, 2753-2753.	1.4	6
431	Diagnostic Criteria and Classification of Myelodysplastic Syndromes. , 2011, , 43-53.		1
432	Karyotype Plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (≥60 Years) Who Benefit From Intensive Post-Induction Consolidation Therapy. <i>Blood</i> , 2011, 118, 2504-2504.	1.4	0

#	ARTICLE	IF	CITATIONS
433	Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. American Journal of Cancer Research, 2011, 1, 531-41.	1.4	11
434	Role of interleukins in the regulation of basophil development and secretion. Current Opinion in Hematology, 2010, 17, 60-66.	2.5	26
435	The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). Blood, 2010, 116, 850-851.	1.4	19
436	How I treat patients with advanced systemic mastocytosis. Blood, 2010, 116, 5812-5817.	1.4	106
437	Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood, 2010, 116, 1548-1558.	1.4	56
438	First annual report of the Austrian CML registry. Wiener Klinische Wochenschrift, 2010, 122, 558-566.	1.9	4
439	KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406). Experimental Hematology, 2010, 38, 782-791.	0.4	10
440	In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Experimental Hematology, 2010, 38, 744-755.	0.4	46
441	H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Experimental Hematology, 2010, 38, 896-907.	0.4	35
442	Refinements in Response Criteria in Systemic Mastocytosis: Reply to a Proposal. European Journal of Haematology, 2010, 85, no-no.	2.2	1
443	Evaluation of the prognostic significance of Eosinophilia and Basophilia in a larger cohort of patients with myelodysplastic syndromes. Cancer, 2010, 116, 2372-2381.	4.1	52
444	Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge. American Journal of Hematology, 2010, 85, 600-606.	4.1	50
445	Neoplastic stem cells: Current concepts and clinical perspectives. Critical Reviews in Oncology/Hematology, 2010, 76, 79-98.	4.4	29
446	Variable presence of <i>KIT</i> ^{D816V} in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). Journal of Pathology, 2010, 220, 586-595.	4.5	152
447	NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells. British Journal of Haematology, 2010, 148, 868-878.	2.5	27
448	Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?. European Journal of Clinical Investigation, 2010, 40, 918-931.	3.4	15
449	Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536. Cancer Research, 2010, 70, 1513-1523.	0.9	86
450	Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Review of Hematology, 2010, 3, 497-516.	2.2	129

#	ARTICLE	IF	CITATIONS
451	Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 1024-1031.e8.	2.9	40
452	Mast cell activation syndrome: Proposed diagnostic criteria. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 1099-1104.e4.	2.9	266
453	Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. <i>Molecular Oncology</i> , 2010, 4, 150-160.	4.6	35
454	High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming <i>KIT</i> mutation D816V. <i>Molecular Oncology</i> , 2010, 4, 335-346.	4.6	44
455	Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 369-378.	1.7	53
456	Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia. <i>Lancet Oncology</i> , The, 2010, 11, 1010-1011.	10.7	2
457	Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. <i>Expert Review of Hematology</i> , 2010, 3, 665-673.	2.2	39
458	Classification and response criteria in mastocytosis: is there a need to revise?. <i>Expert Review of Hematology</i> , 2010, 3, 247-249.	2.2	0
459	Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice. <i>Oncotarget</i> , 2010, 1, 104-19.	1.8	2
460	Standards and impact of hematopathology in myelodysplastic syndromes (MDS). <i>Oncotarget</i> , 2010, 1, 483-96.	1.8	28
461	Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice. <i>Oncotarget</i> , 2010, 1, 104-119.	1.8	6
462	Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS). <i>Oncotarget</i> , 2010, 1, 483-496.	1.8	52
463	BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells.. <i>Blood</i> , 2010, 116, 3382-3382.	1.4	0
464	Partial Characterization and In Vitro Expansion of Putative CLL Precursor/Stem Cells Which Are Dependent on Bone Marrow Microenvironment for Survival. <i>Blood</i> , 2010, 116, 2433-2433.	1.4	1
465	A Combination Vaccine for Allergy and Rhinovirus Infections Based on Rhinovirus-Derived Surface Protein VP1 and a Nonallergenic Peptide of the Major Timothy Grass Pollen Allergen Phl p 1. <i>Journal of Immunology</i> , 2009, 182, 6298-6306.	0.8	80
466	Trimolecular Complex Formation of IgE, Fc μ RI, and a Recombinant Nonanaphylactic Single-Chain Antibody Fragment with High Affinity for IgE. <i>Journal of Immunology</i> , 2009, 182, 4817-4829.	0.8	16
467	The protein tyrosine kinase Tec regulates mast cell function. <i>European Journal of Immunology</i> , 2009, 39, 3228-3238.	2.9	22
468	Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS). <i>Memo - Magazine of European Medical Oncology</i> , 2009, 2, 13-17.	0.5	0

#	ARTICLE	IF	CITATIONS
469	Lenalidomide therapy in systemic mastocytosis. <i>Leukemia Research</i> , 2009, 33, e19-e22.	0.8	13
470	Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. <i>Blood Reviews</i> , 2009, 23, 157-165.	5.7	71
471	Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML. <i>European Journal of Internal Medicine</i> , 2009, 20, 775-778.	2.2	19
472	Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation. <i>Veterinary Immunology and Immunopathology</i> , 2009, 132, 243-250.	1.2	17
473	Expression of Activated STAT5 in Neoplastic Mast Cells in Systemic Mastocytosis. <i>American Journal of Pathology</i> , 2009, 175, 2416-2429.	3.8	72
474	Update on genetic and molecular markers associated with myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2009, 50, 341-348.	1.3	8
475	Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. <i>Blood</i> , 2009, 114, 5342-5351.	1.4	57
476	Interleukin-33: a regulator of basophils. <i>Blood</i> , 2009, 113, 1396-1397.	1.4	10
477	Spectrum, Function, and Value of Targets Expressed in Neoplastic Mast Cells. , 2009, , 107-125.		0
478	Revealing Six Phases of CML Stem Cell Development to Explain Clinical Phenomena Seen in TKI-Treated Patients.. <i>Blood</i> , 2009, 114, 4263-4263.	1.4	0
479	Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review. <i>Wiener Klinische Wochenschrift</i> , 2008, 120, 136-151.	1.9	81
480	Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. <i>Wiener Klinische Wochenschrift</i> , 2008, 120, 697-709.	1.9	9
481	Expression and prognostic significance of different mRNA 5'â€² variants of the oncogene <i>EV11</i> in 266 patients with de novo AML: <i>EV11</i> and <i>MDS1/EV11</i> overexpression both predict short remission duration. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 288-298.	2.8	55
482	Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: A hypothesis supported by unique case reports. <i>Leukemia Research</i> , 2008, 32, 1333-1337.	0.8	13
483	Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy. <i>Leukemia Research</i> , 2008, 32, 1779-1783.	0.8	10
484	The IgE-Reactive Autoantigen Hom s 2 Induces Damage of Respiratory Epithelial Cells and Keratinocytes via Induction of IFN- γ . <i>Journal of Investigative Dermatology</i> , 2008, 128, 1451-1459.	0.7	48
485	Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. <i>British Journal of Haematology</i> , 2008, 142, 361-378.	2.5	57
486	Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFR β . <i>Experimental Hematology</i> , 2008, 36, 1244-1253.	0.4	24

#	ARTICLE	IF	CITATIONS
487	Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis. <i>Experimental Hematology</i> , 2008, 36, 1461-1470.	0.4	19
488	The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia. <i>Molecular Oncology</i> , 2008, 2, 272-281.	4.6	27
489	Mast cell-derived proteases control allergic inflammation through cleavage of IgE. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 197-202.	2.9	43
490	Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease. <i>Human Pathology</i> , 2008, 39, 917-924.	2.0	17
491	Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering. <i>Molecular Immunology</i> , 2008, 45, 2486-2498.	2.2	53
492	Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic Syndrome (MDS). <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1217-1225.	2.0	126
493	Systemic Mastocytosis Associated with Chronic Idiopathic Myelofibrosis. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 58-66.	2.8	64
494	Characterization of Folded Recombinant Der p 5, a Potential Diagnostic Marker Allergen for House Dust Mite Allergy. <i>International Archives of Allergy and Immunology</i> , 2008, 147, 101-109.	2.1	43
495	In Human Macrophages the Complement Component C5a Induces the Expression of Oncostatin M via AP-1 Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 498-503.	2.4	42
496	Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens. <i>Journal of Immunology</i> , 2008, 180, 5466-5476.	0.8	75
497	Disruption of Allergenic Activity of the Major Grass Pollen Allergen Phl p 2 by Reassembly as a Mosaic Protein. <i>Journal of Immunology</i> , 2008, 181, 4864-4873.	0.8	26
498	A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6. <i>Biological Chemistry</i> , 2008, 389, 925-33.	2.5	29
499	Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. <i>Haematologica</i> , 2008, 93, 447-450.	3.5	79
500	Targets and targeted drugs in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 599-599.	1.3	0
501	Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 635-638.	1.3	24
502	Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 604-609.	1.3	7
503	Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. <i>Blood</i> , 2008, 111, 2200-2210.	1.4	85
504	The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. <i>Blood</i> , 2008, 111, 3097-3107.	1.4	78

#	ARTICLE	IF	CITATIONS
505	Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. <i>Blood</i> , 2008, 112, 2463-2473.	1.4	97
506	Leukemic challenge unmasks a requirement for PI3KÎ in NK cell-mediated tumor surveillance. <i>Blood</i> , 2008, 112, 4655-4664.	1.4	48
507	Impact of Age and Comorbidity in Myelodysplastic Syndromes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 927-934.	4.9	37
508	Systemic Mastocytosis. , 2008, 142, 399-419.		23
509	Phenotypic and Functional Characterization of CD34+/CD38-/CD123+ Leukemic Progenitor (Stem) Cells in AML: a Flow Cytometric Approach.. <i>Blood</i> , 2008, 112, 1340-1340.	1.4	1
510	New Prognostic Data on Rare Cytogenetic Abnormalities in MDS: A Collaborative Study of the International Working Group on MDS Cytogenetics. <i>Blood</i> , 2008, 112, 2688-2688.	1.4	2
511	Mastocytosis â€ A Disease of the Hematopoietic Stem Cell. <i>Deutsches A&#x0308;rztblatt International</i> , 2008, 105, 686-92.	0.9	34
512	Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (ObatoclaxÂ®) on Growth and Viability of Canine and Human Neoplastic Mast Cells. <i>Blood</i> , 2008, 112, 861-861.	1.4	0
513	Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial. <i>Blood</i> , 2008, 112, 2973-2973.	1.4	8
514	A Recombinant Hypoallergenic Parvalbumin Mutant for Immunotherapy of IgE-Mediated Fish Allergy. <i>Journal of Immunology</i> , 2007, 178, 6290-6296.	0.8	165
515	The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 13283-13288.	7.1	274
516	Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. <i>Haematologica</i> , 2007, 92, 1451-1459.	3.5	92
517	Antigens Drive Memory IgE Responses in Human Allergy via the Nasal Mucosa. <i>International Archives of Allergy and Immunology</i> , 2007, 142, 133-144.	2.1	78
518	Diagnostic and Subdiagnostic Accumulation of Mast Cells in the Bone Marrow of Patients with Anaphylaxis: Monoclonal Mast Cell Activation Syndrome. <i>International Archives of Allergy and Immunology</i> , 2007, 142, 158-164.	2.1	111
519	Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. <i>Blood</i> , 2007, 110, 4055-4063.	1.4	600
520	Genetic Engineering of the Major Timothy Grass Pollen Allergen, Phl p 6, to Reduce Allergenic Activity and Preserve Immunogenicity. <i>Journal of Immunology</i> , 2007, 179, 1730-1739.	0.8	27
521	A Hypoallergenic Vaccine Obtained by Tail-to-Head Restructuring of Timothy Grass Pollen Profilin, Phl p 12, for the Treatment of Cross-Sensitization to Profilin. <i>Journal of Immunology</i> , 2007, 179, 7624-7634.	0.8	27
522	Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. <i>Blood</i> , 2007, 109, 1678-1686.	1.4	108

#	ARTICLE	IF	CITATIONS
523	Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. <i>Blood</i> , 2007, 109, 3031-3041.	1.4	64
524	Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. <i>Blood</i> , 2007, 110, 661-669.	1.4	43
525	New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. <i>Blood</i> , 2007, 110, 4385-4395.	1.4	719
526	Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. <i>Veterinary Immunology and Immunopathology</i> , 2007, 115, 320-333.	1.2	47
527	Mastocytosis: State of the Art. <i>Pathobiology</i> , 2007, 74, 121-132.	3.8	210
528	Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. <i>Leukemia and Lymphoma</i> , 2007, 48, 1997-2007.	1.3	39
529	Myelodysplastic syndromes, aging, and age: Correlations, common mechanisms, and clinical implications. <i>Leukemia and Lymphoma</i> , 2007, 48, 1900-1909.	1.3	21
530	Biology and clinical features of myeloid neoplasms with inv(3) (q21q26) or t(3;3) (q21q26). <i>Leukemia and Lymphoma</i> , 2007, 48, 2096-2097.	1.3	5
531	Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the International Prognostic Scoring System in Myelodysplastic Syndromes. <i>Clinical Leukemia</i> , 2007, 1, 353-356.	0.2	7
532	Vaccination with genetically modified birch pollen allergens: Immune and clinical effects on oral allergy syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 1013-1016.	2.9	46
533	Eosinophilia in systemic mastocytosis: Clinical and molecular correlates and prognostic significance. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 192-199.	2.9	30
534	A patient with de novo AML M1 and t(16;21) with karyotype evolution. <i>Leukemia Research</i> , 2007, 31, 1319-1321.	0.8	7
535	Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. <i>Leukemia Research</i> , 2007, 31, 727-736.	0.8	478
536	Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: The diagnostic interface. <i>Leukemia Research</i> , 2007, 31, 1461-1468.	0.8	90
537	Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. <i>Leukemia Research</i> , 2007, 31, 1609-1616.	0.8	49
538	Comparison of a Treatment Strategy Combining CCI-779 Plus DTIC Versus DTIC Monotreatment in Human Melanoma in SCID Mice. <i>Journal of Investigative Dermatology</i> , 2007, 127, 2411-2417.	0.7	30
539	Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils. <i>Experimental Hematology</i> , 2007, 35, 108-116.	0.4	34
540	Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. <i>Experimental Hematology</i> , 2007, 35, 1510-1521.	0.4	50

#	ARTICLE	IF	CITATIONS
541	Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib. <i>Blood</i> , 2007, 110, 1541-1541.	1.4	6
542	Prognostic Factors Predicting Survival in De Novo AML Patients Requiring Intensive Care.. <i>Blood</i> , 2007, 110, 2860-2860.	1.4	0
543	The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.. <i>Blood</i> , 2007, 110, 3554-3554.	1.4	0
544	Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.. <i>Blood</i> , 2007, 110, 4556-4556.	1.4	0
545	Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches. <i>Biologics: Targets and Therapy</i> , 2007, 1, 433-48.	3.2	18
546	Expression of Cell Surface Antigens on Mast Cells: Mast Cell Phenotyping. , 2006, 315, 077-090.		16
547	Detection of molecular targets on the surface of CD34+/CD38 ⁺ stem cells in various myeloid malignancies. <i>Leukemia and Lymphoma</i> , 2006, 47, 207-222.	1.3	140
548	Use of interleukin-11 to stimulate platelet production in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2006, 47, 1999-2001.	1.3	2
549	Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. <i>Leukemia and Lymphoma</i> , 2006, 47, 451-460.	1.3	41
550	Evaluation of Angiogenesis and Vascular Endothelial Growth Factor Expression in the Bone Marrow of Patients with Aplastic Anemia. <i>American Journal of Pathology</i> , 2006, 168, 123-130.	3.8	40
551	Diagnostic Evaluation and Classification of Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2006, 26, 515-534.	1.9	46
552	Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: Importance for allergenic activity. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 1336-1343.	2.9	61
553	Immunohistochemical detection of histidine decarboxylase in neoplastic mast cells in patients with systemic mastocytosis. <i>Human Pathology</i> , 2006, 37, 439-447.	2.0	14
554	PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. <i>Blood</i> , 2006, 107, 752-759.	1.4	235
555	The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. <i>Blood</i> , 2006, 108, 3538-3547.	1.4	23
556	Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): Detection of FIP1L1/PDGFR ^{T319I} , classification by WHO criteria, and response to therapy with imatinib. <i>Leukemia Research</i> , 2006, 30, 1201-1205.	0.8	37
557	Urticaria pigmentosa and mastocytosis: The role of immunophenotyping in diagnosis and determining response to treatment. <i>Current Allergy and Asthma Reports</i> , 2006, 6, 282-288.	5.3	27
558	Neoplastic stem cells: A novel therapeutic target in clinical oncology. <i>Cancer</i> , 2006, 107, 2512-2520.	4.1	77

#	ARTICLE	IF	CITATIONS
559	Identification of Basogranulin (BB1) as a Novel Immunohistochemical Marker of Basophils in Normal Bone Marrow and Patients With Myeloproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2006, 125, 273-281.	0.7	50
560	Allergen cleavage by effector cell-derived proteases regulates allergic inflammation. <i>FASEB Journal</i> , 2006, 20, 967-969.	0.5	25
561	Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 897-906.	1.3	11
562	Immunological Characterization and Antibacterial Function of Persisting Granulocytes in Leukemic Patients Receiving Pulse Cytosine Arabinoside-Consolidation Chemotherapy on Days 1, 3, and 5. <i>Journal of Immunology</i> , 2006, 176, 1759-1768.	0.8	5
563	Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils. <i>Blood</i> , 2006, 108, 1365-1365.	1.4	1
564	New and Comprehensive Cytogenetic Prognostication and Categorization in MDS. <i>Blood</i> , 2006, 108, 248-248.	1.4	3
565	Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS. <i>Blood</i> , 2006, 108, 252-252.	1.4	4
566	Identification of Basogranulin (BB1) as a Novel Immunohistochemical Marker of Basophils in Normal Bone Marrow and Patients With Myeloproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2006, 125, 273-281.	0.7	16
567	Prognostic Significance of Serial Determinations of LDH Levels in Primary (De Novo) Myelodysplastic Syndromes. <i>Blood</i> , 2006, 108, 4828-4828.	1.4	0
568	Gain of structure and IgE epitopes by eukaryotic expression of the major Timothy grass pollen allergen, Phl p 1. <i>FEBS Journal</i> , 2005, 272, 217-227.	4.7	32
569	Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. <i>Blood</i> , 2005, 105, 3303-3311.	1.4	226
570	High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. <i>Leukemia Research</i> , 2005, 29, 609-615.	0.8	18
571	Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis. <i>Leukemia Research</i> , 2005, 29, 1227-1232.	0.8	12
572	Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib. <i>Leukemia Research</i> , 2005, 29, 1473-1477.	0.8	13
573	Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation. <i>Cell Research</i> , 2005, 15, 325-335.	12.0	138
574	Stat5 tetramer formation is associated with leukemogenesis. <i>Cancer Cell</i> , 2005, 7, 87-99.	16.8	213
575	An unusual case of myelodysplastic syndrome with prolonged clonal stability, indolent clinical course over a decade, and spontaneous regression of AML in the terminal phase. <i>European Journal of Haematology</i> , 2005, 75, 73-77.	2.2	4
576	Hom s 4, an IgE-Reactive Autoantigen Belonging to a New Subfamily of Calcium-Binding Proteins, Can Induce Th Cell Type 1-Mediated Autoreactivity. <i>Journal of Immunology</i> , 2005, 175, 1286-1294.	0.8	73

#	ARTICLE	IF	CITATIONS
577	Myelomastocytic Leukemia: Evidence for the Origin of Mast Cells from the Leukemic Clone and Eradication by Allogeneic Stem Cell Transplantation. <i>Clinical Cancer Research</i> , 2005, 11, 6787-6792.	7.0	54
578	Delineation of Patterns of Bone Marrow Mast Cell Infiltration in Systemic Mastocytosis. <i>American Journal of Clinical Pathology</i> , 2005, 124, 560-568.	0.7	46
579	Low-Level Expression of Proapoptotic Bcl-2 Interacting Mediator in Leukemic Cells in Patients with Chronic Myeloid Leukemia: Role of BCR/ABL, Characterization of Underlying Signaling Pathways, and Reexpression by Novel Pharmacologic Compounds. <i>Cancer Research</i> , 2005, 65, 9436-9444.	0.9	80
580	Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse. <i>Clinical Cancer Research</i> , 2005, 11, 6536-6543.	7.0	17
581	Indolent Systemic Mastocytosis with Elevated Serum Tryptase, Absence of Skin Lesions, and Recurrent Severe Anaphylactoid Episodes. <i>International Archives of Allergy and Immunology</i> , 2005, 136, 273-280.	2.1	77
582	Evaluation of normal and neoplastic human mast cells for expression of CD172a (SIRP α), CD47, and SHP-1. <i>Journal of Leukocyte Biology</i> , 2005, 77, 984-992.	3.3	9
583	Characterization of Wild-Type Recombinant Bet v 1a as a Candidate Vaccine against Birch Pollen Allergy. <i>International Archives of Allergy and Immunology</i> , 2005, 136, 239-249.	2.1	45
584	Cell Surface Membrane Antigen Phenotype of Human Gastrointestinal Mast Cells. <i>International Archives of Allergy and Immunology</i> , 2005, 138, 111-120.	2.1	25
585	Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. <i>FASEB Journal</i> , 2005, 19, 960-962.	0.5	56
586	CD33 as a target of therapy in acute myeloid leukemia: current status and future perspectives. <i>Leukemia and Lymphoma</i> , 2005, 46, 1115-1120.	1.3	27
587	Mastocytosis: Pathology, genetics, and current options for therapy. <i>Leukemia and Lymphoma</i> , 2005, 46, 35-48.	1.3	180
588	Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. <i>Thrombosis Research</i> , 2005, 115, 59-64.	1.7	99
589	A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 1010-1016.	2.9	83
590	IFN- γ -enhanced allergen penetration across respiratory epithelium augments allergic inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 973-981.	2.9	38
591	Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107. <i>Blood</i> , 2005, 106, 3516-3516.	1.4	1
592	Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis. <i>Blood</i> , 2005, 106, 3518-3518.	1.4	2
593	Heme Oxygenase-1 (HO-1): A Novel KIT D816V-Dependent Target in Neoplastic Human Mast Cells (HMC-1). <i>Blood</i> , 2005, 106, 3521-3521.	1.4	1
594	Phenotyping of Neoplastic (CD34+/CD38~/CD123+) Stem Cells in Myeloid Malignancies Reveals Expression of Multiple Molecular Targets. <i>Blood</i> , 2005, 106, 1381-1381.	1.4	1

#	ARTICLE	IF	CITATIONS
595	Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors.. Blood, 2005, 106, 1987-1987.	1.4	0
596	Bone Marrow Microvessel Density and it's Prognostic Significance in AML. Leukemia and Lymphoma, 2004, 45, 1369-1373.	1.3	31
597	Detection of Trisomy 8 in Donor-Derived Ph ⁺ Cells in a Patient with Ph+Chronic Myeloid Leukemia Successfully Treated with Imatinib (STI571) in Relapse after Allogeneic Transplantation. Leukemia and Lymphoma, 2004, 45, 1453-1458.	1.3	7
598	Splenic Mastocytosis: Report of Two Cases and Detection of the Transforming Somatic C-KIT Mutation D816V. Leukemia and Lymphoma, 2004, 45, 723-729.	1.3	15
599	Identification of Heme Oxygenase-1 As a Novel BCR/ABL-Dependent Survival Factor in Chronic Myeloid Leukemia. Cancer Research, 2004, 64, 3148-3154.	0.9	143
600	A Novel Effective and Safe Consolidation for Patients Over 60 Years with Acute Myeloid Leukemia. Clinical Cancer Research, 2004, 10, 3965-3971.	7.0	25
601	Chronic Myelogenous Leukemia and Myeloproliferative Disease. Hematology American Society of Hematology Education Program, 2004, 2004, 146-162.	2.5	34
602	Molecular Characterization of Polygalacturonases as Grass Pollen-Specific Marker Allergens: Expulsion from Pollen via Submicronic Respirable Particles. Journal of Immunology, 2004, 172, 6490-6500.	0.8	50
603	Generation of an Allergy Vaccine by Disruption of the Three-Dimensional Structure of the Cross-Reactive Calcium-Binding Allergen, Phl p 7. Journal of Immunology, 2004, 172, 5684-5692.	0.8	62
604	Targeted genes in haematology. European Journal of Clinical Investigation, 2004, 34, 1-1.	3.4	14
605	The European Competence Network on Mastocytosis. Wiener Klinische Wochenschrift, 2004, 116, 647-651.	1.9	23
606	Mast cells, masters, and mastocytosis: Development of research since the times of Paul Ehrlich. Wiener Klinische Wochenschrift, 2004, 116, 645-646.	1.9	4
607	Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leukemia Research, 2004, 28, 249-257.	0.8	138
608	Normal bone marrow function over 6 years in a patient with dysplastic hematopoiesis and a complex karyotype. Leukemia Research, 2004, 28, 651-655.	0.8	6
609	Aleukemic Mast Cell Leukemia with Abnormal Immunophenotype and C-kit Mutation D816V. Leukemia and Lymphoma, 2004, 45, 2295-2302.	1.3	29
610	Bone Marrow Mastocytosis Associated with IgM Kappa Plasma Cell Myeloma. Leukemia and Lymphoma, 2004, 45, 801-805.	1.3	29
611	Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. Journal of Allergy and Clinical Immunology, 2004, 114, 3-11.	2.9	157
612	The Basophil-Specific Ectoenzyme E-NPP3 (CD203c) as a Marker for Cell Activation and Allergy Diagnosis. International Archives of Allergy and Immunology, 2004, 133, 317-329.	2.1	218

#	ARTICLE	IF	CITATIONS
613	Immunohistochemical Detection of VEGF in the Bone Marrow of Patients With Chronic Myeloid Leukemia and Correlation With the Phase of Disease. <i>American Journal of Clinical Pathology</i> , 2004, 121, 473-481.	0.7	30
614	Assays for measuring in vitro basophil activation induced by recombinant allergens. <i>Methods</i> , 2004, 32, 265-270.	3.8	43
615	CD25 Indicates the Neoplastic Phenotype of Mast Cells. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1319-1325.	3.7	163
616	The Heme Oxygenase-1-Targeting Compound PEG-ZnPP Inhibits Growth of Imatinib-Resistant BCR/ABL-Transformed Cells.. <i>Blood</i> , 2004, 104, 1986-1986.	1.4	1
617	c-kit D816V Provides a Strong Signal for Myelomastocytic Differentiation and Cluster Formation in Murine Ba/F3 Cells.. <i>Blood</i> , 2004, 104, 485-485.	1.4	4
618	Immunohistochemical Detection of VEGF in the Bone Marrow of Patients With Chronic Myeloid Leukemia and Correlation With the Phase of Disease. <i>American Journal of Clinical Pathology</i> , 2004, 121, 473-481.	0.7	8
619	Histidine Decarboxylase (HDC) as Novel Marker of Immature Neoplastic Mast Cells in Systemic Mastocytosis.. <i>Blood</i> , 2004, 104, 4755-4755.	1.4	1
620	Clinical Course and Prognosis in Mast Cell Proliferative Disorders: A 17 Year Experience in a Single Center.. <i>Blood</i> , 2004, 104, 4741-4741.	1.4	0
621	Enumeration and Immunologic Characterization of Basophils in Normal Bone Marrow and Patients with Myeloproliferative Disorders.. <i>Blood</i> , 2004, 104, 4754-4754.	1.4	0
622	Chronic myeloid leukemia: Pathophysiology, diagnostic parameters, and current treatment concepts. <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 485-504.	1.9	29
623	Treatment concepts for elderly patients with acute myeloid leukemia. <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 505-514.	1.9	5
624	Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS). <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 515-536.	1.9	4
625	Effect of statins on lipoprotein receptor expression in cell lines from human mast cells and basophils. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 507-516.	1.9	9
626	Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. <i>Leukemia Research</i> , 2003, 27, 635-641.	0.8	217
627	Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis. <i>British Journal of Haematology</i> , 2003, 120, 257-265.	2.5	44
628	Diagnosis and treatment of systemic mastocytosis: state of the art. <i>British Journal of Haematology</i> , 2003, 122, 695-717.	2.5	187
629	Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 1227-1241.	2.2	59
630	Induction of Apoptosis in the Human Mast Cell Leukemia Cell Line HMC-1 by Various Antineoplastic Drugs. <i>Leukemia and Lymphoma</i> , 2003, 44, 509-515.	1.3	16

#	ARTICLE	IF	CITATIONS
631	Immunohistochemical Detection of VEGF in the Bone Marrow of Patients With Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2003, 119, 663-671.	0.7	35
632	Simvastatin Reduces the Expression of Adhesion Molecules in Circulating Monocytes From Hypercholesterolemic Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 397-403.	2.4	138
633	Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3. <i>Journal of Leukocyte Biology</i> , 2003, 73, 107-117.	3.3	27
634	Formation of Disulfide Bonds and Homodimers of the Major Cat Allergen Fel d 1 Equivalent to the Natural Allergen by Expression in <i>Escherichia coli</i> . <i>Journal of Biological Chemistry</i> , 2003, 278, 40144-40151.	3.4	71
635	Morphologic and Immunophenotypic Properties of Neoplastic Cells in a Case of Mast Cell Sarcoma. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1013-1019.	3.7	52
636	New Aspects in Thrombotic Research: Complement Induced Switch in Mast Cells from a Profibrinolytic to a Prothrombotic Phenotype. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2003, 33, 438-441.	0.3	49
637	Molecular characterization of recombinant T1, a non-allergenic periwinkle (<i>Catharanthus roseus</i>) protein, with sequence similarity to the Bet v 1 plant allergen family. <i>Biochemical Journal</i> , 2003, 373, 261-269.	3.7	20
638	Immunohistochemical Detection of VEGF in the Bone Marrow of Patients With Acute Myeloid Leukemia: Correlation Between VEGF Expression and the FAB Category. <i>American Journal of Clinical Pathology</i> , 2003, 119, 663-671.	0.7	15
639	Smouldering Mastocytosis: A Novel Subtype of Systemic Mastocytosis with Slow Progression. <i>International Archives of Allergy and Immunology</i> , 2002, 127, 137-139.	2.1	61
640	Spectrum of Associated Clonal Hematologic Non-Mast Cell Lineage Disorders Occurring in Patients with Systemic Mastocytosis. <i>International Archives of Allergy and Immunology</i> , 2002, 127, 140-142.	2.1	70
641	Detection of Novel CD Antigens on the Surface of Human Mast Cells and Basophils. <i>International Archives of Allergy and Immunology</i> , 2002, 127, 299-307.	2.1	76
642	Serum Tryptase Levels in Patients with Mastocytosis: Correlation with Mast Cell Burden and Implication for Defining the Category of Disease. <i>International Archives of Allergy and Immunology</i> , 2002, 128, 136-141.	2.1	184
643	Individual Hymenoptera Venom Compounds Induce Upregulation of the Basophil Activation Marker Ectonucleotide Pyrophosphatase/Phosphodiesterase 3 (CD203c) in Sensitized Patients. <i>International Archives of Allergy and Immunology</i> , 2002, 129, 160-168.	2.1	66
644	Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1194-1199.	2.4	340
645	Purification, Structural and Immunological Characterization of a Timothy Grass (<i>Phleum pratense</i>) Pollen Allergen, Phl p 4, with Cross-Reactive Potential. <i>Biological Chemistry</i> , 2002, 383, 1383-96.	2.5	21
646	Kit and $c\text{-kit}$ Mutations in Mastocytosis: A Short Overview with Special Reference to Novel Molecular and Diagnostic Concepts. <i>International Archives of Allergy and Immunology</i> , 2002, 127, 110-114.	2.1	130
647	Histopathological and Immunohistochemical Aspects of Mastocytosis. <i>International Archives of Allergy and Immunology</i> , 2002, 127, 115-117.	2.1	77
648	Activation of Human Mast Cells through Stem Cell Factor Receptor (KIT) Is Associated with Expression of bcl-2. <i>International Archives of Allergy and Immunology</i> , 2002, 129, 228-236.	2.1	29

#	ARTICLE	IF	CITATIONS
649	FDG Positron Emission Tomography in Patients with Systemic Mastocytosis. American Journal of Roentgenology, 2002, 179, 1235-1237.	2.2	17
650	Stem Cell Factor-induced Bone Marrow Mast Cell Hyperplasia Mimicking Systemic Mastocytosis (SM): Histopathologic and Morphologic Evaluation with Special Reference to Recently Established SM-criteria. Leukemia and Lymphoma, 2002, 43, 575-582.	1.3	24
651	C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood, 2002, 100, 517-523.	1.4	128
652	BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1 β , through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood, 2002, 100, 3767-3775.	1.4	275
653	Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. Blood, 2002, 99, 4246-4247.	1.4	25
654	Recombinant Carp Parvalbumin, the Major Cross-Reactive Fish Allergen: A Tool for Diagnosis and Therapy of Fish Allergy. Journal of Immunology, 2002, 168, 4576-4584.	0.8	223
655	Increased Angiogenesis in the Bone Marrow of Patients with Systemic Mastocytosis. American Journal of Pathology, 2002, 160, 1639-1645.	3.8	45
656	Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. Journal of Allergy and Clinical Immunology, 2002, 110, 102-109.	2.9	156
657	Tryptase a Novel Biochemical Marker of Acute Myeloid Leukemia. Leukemia and Lymphoma, 2002, 43, 2257-2261.	1.3	42
658	Mast cells, thrombosis, and fibrinolysis. Thrombosis Research, 2002, 105, 359-365.	1.7	16
659	Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. European Journal of Immunology, 2002, 32, 270-280.	2.9	76
660	Conversion of grass pollen allergen-specific human IgE into a protective IgG1 antibody. European Journal of Immunology, 2002, 32, 2156.	2.9	73
661	Signal Transduction-Associated and Cell Activation-Linked Antigens Expressed in Human Mast Cells. International Journal of Hematology, 2002, 75, 357-362.	1.6	6
662	Response to the letter of Dr. Karin Hartmann and Dr. Beate M. Henz. Leukemia Research, 2002, 26, 485-486.	0.8	12
663	A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. Leukemia Research, 2002, 26, 601-606.	0.8	32
664	Detection of c-kit point mutation Asp-816 \rightarrow Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leukemia Research, 2002, 26, 979-984.	0.8	61
665	Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. The Hematology Journal, 2002, 3, 90-94.	1.4	54
666	Isolation and Culture of Mast Cells and Basophils. , 2002, , 241-257.		0

#	ARTICLE	IF	CITATIONS
667	A molecular model of type I allergy: Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-Fc ϵ RI interaction and reacts with receptor-bound IgE. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, 409-416.	2.9	23
668	Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: Evidence for expression of CD2, CD117/Kit, and bcl-xL. <i>Human Pathology</i> , 2001, 32, 545-552.	2.0	109
669	Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. <i>Blood</i> , 2001, 98, 2200-2209.	1.4	130
670	The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3. <i>Blood</i> , 2001, 97, 3303-3305.	1.4	134
671	Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. <i>Blood</i> , 2001, 98, 3784-3792.	1.4	48
672	Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. <i>Blood</i> , 2001, 98, 2580-2583.	1.4	58
673	Mutation analysis of <i>C-KIT</i> in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. <i>British Journal of Haematology</i> , 2001, 113, 357-364.	2.5	135
674	Characterization of 123I-vascular endothelial growth factor-binding sites expressed on human tumour cells: Possible implication for tumour scintigraphy. <i>International Journal of Cancer</i> , 2001, 91, 789-796.	5.1	66
675	Amplification of ribosomal RNA genes in acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2001, 32, 11-17.	2.8	12
676	IgA cross-reactivity between a nuclear autoantigen and wheat proteins suggests molecular mimicry as a possible pathomechanism in celiac disease. <i>European Journal of Immunology</i> , 2001, 31, 918-928.	2.9	19
677	Amplification of the AML1(CBFA2) gene on ring chromosomes in a patient with acute myeloid leukemia and a constitutional ring chromosome 21. <i>Cancer Genetics and Cytogenetics</i> , 2001, 124, 42-46.	1.0	38
678	Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. <i>Leukemia Research</i> , 2001, 25, 287-294.	0.8	38
679	A case of "smouldering" mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. <i>Leukemia Research</i> , 2001, 25, 627-634.	0.8	43
680	Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. <i>Leukemia Research</i> , 2001, 25, 543-551.	0.8	211
681	Diagnostic criteria and classification of mastocytosis: a consensus proposal. <i>Leukemia Research</i> , 2001, 25, 603-625.	0.8	1,020
682	Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. <i>Leukemia Research</i> , 2001, 25, 595-602.	0.8	67
683	Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. <i>Leukemia Research</i> , 2001, 25, 529-536.	0.8	206
684	Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. <i>Leukemia Research</i> , 2001, 25, 563-570.	0.8	124

#	ARTICLE	IF	CITATIONS
685	Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. <i>FASEB Journal</i> , 2001, 15, 2042-2044.	0.5	117
686	Molecular and Immunological Characterization of Arginine Kinase from the Indianmeal Moth, <i>Plodia interpunctella</i> , a Novel Cross-Reactive Invertebrate Pan-Allergen. <i>Journal of Immunology</i> , 2001, 167, 5470-5477.	0.8	176
687	Hymenoptera-Venom-Induced Upregulation of the Basophil Activation Marker Ecto-Nucleotide Pyrophosphatase/Phosphodiesterase 3 in Sensitized Individuals. <i>International Archives of Allergy and Immunology</i> , 2001, 126, 335-342.	2.1	63
688	Characterization of Human Prostate Mast Cells and Their Increase in Periprostatic Vein Thrombosis. <i>American Journal of Clinical Pathology</i> , 2001, 116, 97-106.	0.7	64
689	Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1. <i>FASEB Journal</i> , 2001, 15, 2045-2047.	0.5	115
690	Amplification of the <i>MLL</i> gene on double minutes, a homogeneously staining region, and ring chromosomes in five patients with acute myeloid leukemia or myelodysplastic syndrome. <i>Genes Chromosomes and Cancer</i> , 2000, 27, 380-386.	2.8	76
691	Tumor necrosis factor α promotes the expression of stem cell factor in synovial fibroblasts and their capacity to induce mast cell chemotaxis. <i>Arthritis and Rheumatism</i> , 2000, 43, 164-174.	6.7	52
692	Reciprocal Translocation (3;5)(q26;q22) and Possible BCHE Gene Involvement in an Unusual Myelogenous Disorder with both Myeloproliferative and Dysplastic Features. <i>Cancer Genetics and Cytogenetics</i> , 2000, 121, 133-138.	1.0	2
693	A Human Monoclonal IgE Antibody Defines a Highly Allergenic Fragment of the Major Timothy Grass Pollen Allergen, Phl p 5: Molecular, Immunological, and Structural Characterization of the Epitope-Containing Domain. <i>Journal of Immunology</i> , 2000, 165, 3849-3859.	0.8	77
694	Clinical and Biologic Diversity of Leukemias Occurring in Patients with Mastocytosis. <i>Leukemia and Lymphoma</i> , 2000, 37, 473-486.	1.3	101
695	Autoantibody Reactivity in a Case of Schnitzler's Syndrome: Evidence for a Th1-Like Response and Detection of IgG2 Anti-Fc μ R1 \pm Antibodies. <i>International Archives of Allergy and Immunology</i> , 2000, 122, 279-286.	2.1	14
696	Role of Mast Cells in Endogenous Fibrinolysis and Related (Patho)physiological Processes. , 2000, , 497-505.		4
697	Calcium-dependent immunoglobulin E recognition of the apo- and calcium-bound form of a cross-reactive two EF-hand timothy grass pollen allergen, Phl p 7. <i>FASEB Journal</i> , 1999, 13, 843-856.	0.5	105
698	B cell epitopes of the major timothy grass pollen allergen, Phl p 1, revealed by gene fragmentation as candidates for immunotherapy. <i>FASEB Journal</i> , 1999, 13, 1277-1290.	0.5	73
699	An in vitro Model for the Allergen-IgE-Fc μ R1 Interaction. <i>International Archives of Allergy and Immunology</i> , 1999, 118, 116-118.	2.1	3
700	Characterization of IgE-Reactive Autoantigens in Atopic Dermatitis 1. Subcellular Distribution and Tissue-Specific Expression. <i>International Archives of Allergy and Immunology</i> , 1999, 120, 108-116.	2.1	29
701	Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. <i>European Journal of Immunology</i> , 1999, 29, 2026-2036.	2.9	138
702	Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific Immunotherapy. <i>International Archives of Allergy and Immunology</i> , 1999, 118, 218-219.	2.1	32

#	ARTICLE	IF	CITATIONS
703	Mast cells are augmented in deep vein thrombosis and express a profibrinolytic phenotype. Human Pathology, 1999, 30, 188-194.	2.0	25
704	The immunoglobulin-like modules C1 μ 3 and I \pm 2 are the minimal units necessary for human IgE-Fc μ RI interaction. Journal of Clinical Investigation, 1999, 103, 1571-1578.	8.2	29
705	Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis and Rheumatism, 1998, 41, 233-245.	6.7	100
706	Effects of dental amalgam and heavy metal cations on cytokine production by peripheral blood mononuclear cells in vitro. , 1998, 42, 76-84.		12
707	Molecular Characterization of an Autoallergen, Hom s 1, Identified by Serum IgE from Atopic Dermatitis Patients11Part of this manuscript was previously published in the proceedings of the 21st Symposium of the Collegium Internationale Allergologicum "Allergy " A Disease of Modern Society", Int Arch Allergy Immunol 113:209-212, 1998. Journal of Investigative Dermatology, 1998, 111, 1178-1183.	0.7	122
708	Recombinant human megakaryocyte growth and development factor increases levels of circulating haemopoietic progenitor cells post chemotherapy in patients with acute myeloid leukaemia. British Journal of Haematology, 1998, 102, 535-543.	2.5	14
709	Identification of common allergenic structures in mugwort and ragweed pollen. Journal of Allergy and Clinical Immunology, 1998, 101, 196-206.	2.9	96
710	Phenotypic Characterization of Human Skin Mast Cells by Combined Staining with Toluidine Blue and CD Antibodies. Journal of Investigative Dermatology, 1998, 111, 689-695.	0.7	84
711	The Immunoglobulin E "Allergen Interaction: A Target for Therapy of Type I Allergic Diseases. International Archives of Allergy and Immunology, 1998, 116, 167-176.	2.1	28
712	What Have Mast Cells To Do with Edema Formation, the Consecutive Repair and Fibrinolysis?. International Archives of Allergy and Immunology, 1998, 115, 2-8.	2.1	39
713	Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients. FASEB Journal, 1998, 12, 1559-1569.	0.5	120
714	Diagnostic Value of Immunostaining for Tryptase in Patients With Mastocytosis. American Journal of Surgical Pathology, 1998, 22, 1132-1140.	3.7	225
715	Division of the Major Birch Pollen Allergen, Bet v 1, into Two Non-Anaphylactic Fragments. International Archives of Allergy and Immunology, 1997, 113, 246-248.	2.1	19
716	Immunophenotypic and functional characterization of human tonsillar mast cells. Journal of Leukocyte Biology, 1997, 61, 592-599.	3.3	25
717	Expression of fibrinolytic antigens in redistributed cardiac mast cells in auricular thrombosis. Human Pathology, 1997, 28, 1283-1290.	2.0	9
718	The c-kit Ligand Stem Cell Factor and Anti-IgE Promote Expression of Monocyte Chemoattractant Protein-1 in Human Lung Mast Cells. Blood, 1997, 90, 4438-4449.	1.4	76
719	Thrombin Augments Vascular Cell-dependent Migration of Human Mast Cells: Role of MGF. Thrombosis and Haemostasis, 1997, 77, 577-584.	3.4	24
720	The c-kit Ligand Stem Cell Factor and Anti-IgE Promote Expression of Monocyte Chemoattractant Protein-1 in Human Lung Mast Cells. Blood, 1997, 90, 4438-4449.	1.4	6

#	ARTICLE	IF	CITATIONS
721	Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. <i>Journal of Allergy and Clinical Immunology</i> , 1996, 98, 389-399.	2.9	44
722	Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2. <i>Journal of Allergy and Clinical Immunology</i> , 1996, 97, 95-103.	2.9	43
723	High-Level Expression in <i>Escherichia coli</i> and Purification of Recombinant Plant Profilins: Comparison of IgE-Binding Capacity and Allergenic Activity. <i>Biochemical and Biophysical Research Communications</i> , 1996, 226, 42-50.	2.1	20
724	In vitro and in vivo studies of three radiolabelled somatostatin analogues: ¹²³ I-Octreotide (OCT), ¹²³ I-Tyr-3-OCT and ¹¹¹ In-TIRA-d-Phe-1-OCT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 1388-1399.	2.1	31
725	Mast Cell-Lineage Versus Basophil Lineage Involvement in Myeloproliferative and Myelodysplastic Syndromes: Diagnostic Role of Cell-Immunophenotyping. <i>Leukemia and Lymphoma</i> , 1996, 22, 187-204.	1.3	41
726	Immunophenotypic Analysis of HL-60 Cells during Basophilic Differentiation. <i>International Archives of Allergy and Immunology</i> , 1996, 110, 252-260.	2.1	7
727	Immunoglobulin E Response to Human Proteins in Atopic Patients. <i>Journal of Investigative Dermatology</i> , 1996, 107, 203-208.	0.7	122
728	Recombinant Allergens. <i>Advances in Experimental Medicine and Biology</i> , 1996, , 185-196.	1.6	8
729	Cytokines involved in growth and differentiation of human basophils and mast cells. <i>Experimental Dermatology</i> , 1995, 4, 255-259.	2.9	38
730	Immunophenotypic Characterization of Human Basophils and Mast Cells. <i>Chemical Immunology and Allergy</i> , 1995, 61, 34-48.	1.7	13
731	Characterization of LDL and VLDL Binding Sites on Human Basophils and Mast Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 17-26.	2.4	11
732	Purification of human basophils and mast cells by multistep separation technique and mAb to CDw17 and. <i>Journal of Immunological Methods</i> , 1995, 182, 115-129.	1.4	51
733	Increase and Redistribution of Cardiac Mast Cells in Auricular Thrombosis. <i>Circulation</i> , 1995, 91, 275-283.	1.6	47
734	Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors. <i>New England Journal of Medicine</i> , 1994, 331, 1116-1121.	27.0	243
735	Does Cord Blood Contain Enough Progenitor Cells for Transplantation?. <i>Stem Cells and Development</i> , 1994, 3, 291-298.	1.0	16
736	The riddle of the mast cell: kit(CD117)-ligand as the missing link?. <i>Trends in Immunology</i> , 1994, 15, 111-114.	7.5	117
737	The phenotype of human eosinophils, basophils, and mast cells. <i>Journal of Allergy and Clinical Immunology</i> , 1994, 94, 1177-1183.	2.9	58
738	Molecular characterization of dog albumin as a cross-reactive allergen. <i>Journal of Allergy and Clinical Immunology</i> , 1994, 93, 614-627.	2.9	98

#	ARTICLE	IF	CITATIONS
739	Inhibition of Stem Cell Factor Dependent Formation of Human Mast Cells by Interleukin-3 and Interleukin-4. <i>International Archives of Allergy and Immunology</i> , 1994, 105, 264-268.	2.1	44
740	Cell Surface Structures on Human Basophils and Mast Cells: Biochemical and Functional Characterization. <i>Advances in Immunology</i> , 1992, 52, 333-423.	2.2	181
741	Identification of common allergenic structures in hazel pollen and hazelnuts: A possible explanation for sensitivity to hazelnuts in patients allergic to tree pollen. <i>Journal of Allergy and Clinical Immunology</i> , 1992, 90, 927-936.	2.9	265
742	Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: Effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts. <i>Medical and Pediatric Oncology</i> , 1992, 20, 18-22.	1.0	5
743	The growth and differentiation of mast cells. <i>Progress in Growth Factor Research</i> , 1991, 3, 27-41.	1.6	44
744	Further Characterization of Surface Membrane Structures Expressed on Human Basophils and Mast Cells. <i>International Archives of Allergy and Immunology</i> , 1990, 91, 198-203.	2.1	102
745	Why clinicians should be interested in Interleukin-3. <i>Blut</i> , 1990, 61, 338-345.	1.2	11
746	The human basophil. <i>Critical Reviews in Oncology/Hematology</i> , 1990, 10, 327-352.	4.4	48
747	Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. , 0, .		1
748	Mastocytosis â€œ A Disease of the Hematopoietic Stem Cell: In reply. <i>Deutsches A&#x0308;rztblatt International</i> , 0, , .	0.9	1